ストックスクリーナーアプリを入手
2.98
0.67%
-0.02
アフターアワーズ：
2.98
前日終値:
$3.00
開ける：
$2.98
24時間の取引高:
7,607
Relative Volume:
0.67
時価総額：
$9.06M
収益：
-
当期純損益:
$2.81M
株価収益率:
-0.2077
EPS:
-14.3497
ネットキャッシュフロー:
$7.14M
1週間 パフォーマンス:
-2.61%
1か月 パフォーマンス:
-9.38%
6か月 パフォーマンス:
-8.59%
1年 パフォーマンス:
-33.24%
1日の値動き範囲:
$2.915
$3.2699
1週間の範囲:
$2.915
$3.2699
52週間の値動き範囲:
$2.51
$5.55
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
名前
Kiora Pharmaceuticals Inc
セクター
電話
781-788-8869
住所
332 ENCINITAS BOULEVARD, ENCINITAS
KPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.98 | 9.31M | 0 | 2.81M | 7.14M | -14.35 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
Kiora Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Q1 Earnings Estimate for KPRX Issued By HC Wainwright - Defense World
Persistent Epithelial Defect Market on Track for Major - openPR.com
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiora Pharmaceuticals Reports First Quarter Results; Initiating - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 | KPRX - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 - Stock Titan
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy | KPRX Stock News - GuruFocus
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy - Newsfile
Kiora Pharmaceuticals (KPRX) Projected to Post Quarterly Earnings on Friday - Defense World
Corneal Epithelial Defect Therapeutics Market Size in 7MM - openPR.com
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile
Kiora Unveils Latest Progress on Two Phase 2 Retinal Disease Treatments - Stock Titan
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - The Globe and Mail
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
Kiora Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - TradingView
Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (KPRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile
Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 - MSN
Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria
Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 - StockTitan
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance
January 2025's Top US Penny Stocks To Consider - Yahoo Finance
Kiora Pharmaceuticals, Inc. Announces Promotion of Melissa Tosca to Chief Financial Officer - Marketscreener.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World
3 US Penny Stocks With Market Caps Under $200M - Simply Wall St
US Penny Stocks: 3 Picks With Market Caps Below $400M - Yahoo Finance
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Cerus And 2 Other US Penny Stocks With Promising Potential - Yahoo Finance
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
US Penny Stocks To Watch In January 2025 - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $80M - simplywall.st
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World
Retinitis Pigmentosa Treatment Market Report: Detailed - openPR
Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail
Persistent Epithelial Defect Market Statistics Expected - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Kiora Pharmaceuticals Inc (KPRX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):